Literature DB >> 9810347

[The no-reflow phenomenon: its incidence and clinical characteristics in a series of cases].

E Vallejo1, M A Peña-Duque, O Noroño, E Ban Hayashi, J Gaspar, R Villavicencio, M A Martínez Ríos.   

Abstract

The no-reflow phenomenon refers to the inability to reperfuse myocardial tissue despite removal of an occlusion of a coronary artery. No reflow is a complication that may occur after revascularization of patients. This study examined the incidence and, clinical characteristics of no-reflow in a patient population treated with conventional percutaneous transluminal coronary angioplasty at the Instituto Nacional de Cardiología "Ignacio Chávez". We reviewed 204 elective angioplasties and 62 direct angioplasties; 14 patients were included (4 from the first group and 10 from the second group). No-reflow were more frequently in men, the mean age was 56 years and diabetes and smoking were the risk factors more frequently reported. No-reflow was found in left anterior descending coronary artery in 7 patients, the time of reperfusion, in direct angioplasty, was 10.6 hours (mean) and the strategy most frequently used to reestablish normal anterograde flow was intracoronary verapamil. The overall incidence of no-reflow for the two modalities was 5.2% (16.12% for direct angioplasty and 1.9% for elective angioplasty). The current study shows that the no-reflow phenomenon is not uncommon after angioplasty; no-reflow appears higher than the previous reports for both modalities of treatment.

Entities:  

Mesh:

Year:  1998        PMID: 9810347

Source DB:  PubMed          Journal:  Arch Inst Cardiol Mex


  4 in total

1.  Multilayer longitudinal strain can help predict the development of no-reflow in patients with acute coronary syndrome without ST elevation.

Authors:  Adem Atıcı; Hasan Ali Barman; Emre Erturk; Omer Faruk Baycan; Serdar Fidan; Koray Celal Demirel; Ramazan Asoglu; Koray Demir; Fatih Ozturk; Ali Elitok; Erugrul Okuyan; Irfan Sahin
Journal:  Int J Cardiovasc Imaging       Date:  2019-05-15       Impact factor: 2.357

2.  Distal administration of very high doses of intracoronary adenosine for the treatment of resistant no-reflow.

Authors:  Mohammad-Reza Movahed; Gurpreet Baweja
Journal:  Exp Clin Cardiol       Date:  2008

3.  Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon.

Authors:  Tao Qin; Lu Xie; Meng-Hua Chen
Journal:  BMC Cardiovasc Disord       Date:  2013-09-10       Impact factor: 2.298

4.  Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention.

Authors:  Zhihua Pang; Wei Zhao; Zhuhua Yao
Journal:  Med Sci Monit       Date:  2017-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.